Abstract
The use of bone morphogenetic proteins (BMPs) in treating the clinical challenge posed by fracture delayed and non-union is still under investigation. When used to supplement basic surgical management clinical trials while few in number have demonstrated that BMPs are effective and safe for human application and have an efficacy comparable with that of autologous bone-grafting and eliminate donor site morbidity and reduces the risk of infection at the recipient site. Level one evidence has shown that recombinant human bone morphogenetic protein-7 (rh-BMP-7 or OP-1) is a reasonable alternative to autologous bone grafting in the treatment of long bone non-unions. The use of bone morphogenetic proteins (BMPs) in treating the clinical challenge posed by fracture delayed and non-union is still under investigation. When used to supplement basic surgical management clinical trials while few in number have demonstrated that BMPs are effective and safe for human application and have an efficacy comparable with that of autologous bone-grafting and eliminate donor site morbidity and reduces the risk of infection at the recipient site. Level one evidence has shown that recombinant human bone morphogenetic protein-7 (rh-BMP-7 or OP-1) is a reasonable alternative to autologous bone grafting in the treatment of long bone non-unions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
